Analysis of a Structural Polymorphism in the 5-HT2A Receptor and Clinical Response to Clozapine

Overview

Journal Neurosci Lett

Specialty Neurology

Date 1996 Oct 18

PMID 8916101

Citations 27

Authors

M J Arranz

D A Collier

J Munro

P Sham

G Kirov

M Sodhi

G Roberts

J Price

R W Kerwin

Affiliations

Soon will be listed here.

Abstract

Clozapine is an atypical antipsychotic with affinity for a broad range of receptors, including serotonin (5-HT) and dopamine receptors. It is successful in treating about 60% of patients refractory to other antipsychotic drugs. Since genetic variation in clozapine's neurotransmitter receptor targets may affect clinical response through altering drug binding or receptor expression, we have studied a His452Tyr polymorphism in the 5-HT2A receptor (HTR2A) in a sample of 153 schizophrenic patients undergoing clozapine treatment and 178 normal controls. An association was found between the allele Tyr452 and poor clinical response.

Citing Articles

Efficacy of atypical antipsychotics in schizophrenia patients: effects of 5-HTR SNPs.

Liu K, Zhang B, Chen Z, Chen F, Li Z, Gao Y Ann Gen Psychiatry. 2025; 24(1):10.

PMID: 39966797 PMC: 11837449. DOI: 10.1186/s12991-025-00547-z.

Investigating DRD2 and HTR2A polymorphisms in treatment-resistant schizophrenia: a comparative analysis with other treatment-resistant mental disorders and the healthy state.

Del Casale A, Gentile G, Lardani S, Modesti M, Arena J, Zocchi C Eur Arch Psychiatry Clin Neurosci. 2025; .

PMID: 39934320 DOI: 10.1007/s00406-025-01970-9.

Impact of Pharmacogenetic Testing on Clozapine Treatment Efficacy in Patients with Treatment-Resistant Schizophrenia.

Sanguesa E, Fernandez-Egea E, Concha J, Garcia C, Ribate M Biomedicines. 2024; 12(3).

PMID: 38540209 PMC: 10967865. DOI: 10.3390/biomedicines12030597.

Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives.

Jiao S, Cao T, Cai H Front Pharmacol. 2022; 13:1005702.

PMID: 36313375 PMC: 9597880. DOI: 10.3389/fphar.2022.1005702.

Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.

Shad M Behav Sci (Basel). 2021; 11(7).

PMID: 34209185 PMC: 8301006. DOI: 10.3390/bs11070097.